Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 4/20 | 0.52 |
| ▸ | SCN9A | Q15858 | 10/20 | 0.49 |
| ▸ | SPR | P35270 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 4/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2390098 | 0.92 | NAMPT (0.51) | NAMPTSCN9ASPRKDM1AROCK2 | |
| SCHEMBL2390745 | 0.85 | NAMPT (0.54) | NAMPTSCN9ASPRKDM1AROCK2 | |
| SCHEMBL2486347 | 0.85 | NAMPT (0.53) | NAMPTSPRKDM1AROCK2 | |
| SCHEMBL2388910 | 0.83 | SCN9A (0.57) | NAMPTSCN9ASPRKDM1AROCK2 | |
| SCHEMBL2388609 | 0.82 | NAMPT (0.51) | NAMPTSCN9ASPRKDM1AROCK2 | |
| SCHEMBL2390964 | 0.82 | NAMPT (0.53) | NAMPTSCN9ASPRKDM1AROCK2 | |
| SCHEMBL2390194 | 0.81 | NAMPT (0.54) | NAMPTSPRKDM1AROCK2 | |
| SCHEMBL2390814 | 0.81 | NAMPT (0.56) | NAMPTSCN9ASPRKDM1AROCK2 | |
| SCHEMBL2387834 | 0.80 | NAMPT (0.65) | NAMPTSPRKDM1AROCK2 | |
| SCHEMBL2389804 | 0.80 | NAMPT (0.55) | NAMPTSCN9ASPRKDM1AROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2375904-B1 | BIARYL CARBOXAMIDES | MERCK SHARP & DOHME (US) | 2014-05-28 | — | — | EP | claimed |
| US-8367679-B2 | Biaryl carboxamides | MERCK SHARP & DOHME CORP. (US) | 2013-02-05 | — | — | US | claimed |
| US-20110230498-A1 | BIARYL CARBOXAMIDES | MERCK SHARP & DOHME CORP. | 2011-09-22 | — | — | US | claimed |
| EP-2375904-B1 | BIARYL CARBOXAMIDES | MERCK SHARP & DOHME (US) | 2014-05-28 | — | — | EP | disclosed |
| US-8367679-B2 | Biaryl carboxamides | MERCK SHARP & DOHME CORP. (US) | 2013-02-05 | — | — | US | disclosed |
| EP-2375904-A1 | BIARYL CARBOXAMIDES | Merck Sharp & Dohme Corp. (US) | 2011-10-19 | — | — | EP | disclosed |
| US-20110230498-A1 | BIARYL CARBOXAMIDES | MERCK SHARP & DOHME CORP. | 2011-09-22 | — | — | US | disclosed |
| WO-2010077624-A1 | BIARYL CARBOXAMIDES | MERCK SHARP & DOHME CORP. (US) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230498-A1 | BIARYL CARBOXAMIDES | PAFAH1B3, PAFAH1B2, FAAH2 | NAMPT 2170/4885SCN9A 1077/4885SPR 2765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.